Recruiting
Phase 1

Psilocybin

Sponsor:

Charles Raison

Code:

NCT07719088

Conditions

Aging

Longevity

Biomarkers of Aging

Eligibility Criteria

Sex: All

Age: 60 - 70+

Healthy Volunteers: Accepted

Interventions

Psilocybin (Usona Institute)

Study Details

Brief summary:

The LONG-LIFE study is a randomized Phase I, dose-ranging trial designed to evaluate whether psilocybin impacts aging-related biomarkers, cognitive function, and purpose/meaning in life in medically stable older adults.

Up to 50 participants will be enrolled aged 60-80 who will be randomized with equal allocation to one of four intervention groups: (1) receipt of one 25 mg dose of psilocybin; (2) receipt of two 25 mg doses of psilocybin separated by four weeks; (3) receipt of three 25 mg doses, with each dose separated by four weeks; or (4) wait-list comparator condition that does not receive psilocybin. Biomarkers of aging, cognitive performance, and behavioral measures will be assessed at baseline and longitudinally over a 12-month follow-up period. The primary endpoint occurs at the Week 16 visit. Participants randomized to the wait-list condition will be offered a single 25 mg dose of psilocybin following conclusion of the 12-month follow-up period.

Findings from this Phase I study will inform dose selection for a Phase II study should results indicate a potential impact of psilocybin on relevant study endpoints.

Conditions

Aging

Longevity

Biomarkers of Aging

Study ID

NCT07719088

Start date

Nov 16, 2026

Status verified date

Nov, 2026

Completion date

Dec, 2028

Anticipated

Primary completion date

Apr, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 60 - 70+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • English speaking and able to provide informed consent and complete study procedures
  • Medically healthy, as determined by the screening physician, with no significant medical conditions that would interfere with participation or affect the safety of the subject.

Exclusion Criteria:

  • History or presence of any psychiatric or medical condition that, in the opinion of the investigator, could pose a safety risk, interfere with participation, or confound study results.
  • Abnormal ECG at screening that may increase risk during participation (e.g., prolonged QTc, arrhythmias, or other clinically significant findings as determined by the study physician).
  • Unwilling or unable to discontinue medications that may interfere with study participation, as determined by the investigator.

Study Design

Enrollment

50 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Other

Interventions and Outcome Measures

Arms

experimental: One 25mg Dose of Psilocybin

Participants in this arm will receive one 25mg dose of psilocybin paired with therapeutic support.

experimental: Two 25mg Doses of Psilocybin

Participants in this arm will receive two 25mg doses of psilocybin approximately 4 weeks apart paired with therapeutic support.

experimental: Three 25mg Doses of Psilocybin

Participants in this arm will receive three 25mg doses of psilocybin approximately 4 weeks apart paired with therapeutic support.

no intervention: Wait-list Comparator

Participants in this arm will not receive psilocybin as part of the main study but will be given the opportunity to receive a single 25mg dose of psilocybin with therapeutic support after their study participation is complete.

Interventions

Psilocybin (Usona Institute)

25mg capsule of psilocybin

Primary outcome measure

  • Change in Epigenetic/Biological Clock Profiling from Baseline to Week 4 and Week 16 [ Time Frame: Change from Baseline to Week 4 and Week 16 ]
  • Change in Purpose in Life (PIL) from Baseline to Week 4 and Week 16 [ Time Frame: Change from Baseline to Week 4 and Week 16 ]

Central Contacts and Locations

Central contacts

Locations

Vail Health Behavioral Health

Recruiting

Edwards, Colorado, United States, 81632

Contacts

More Information

Sponsor

Charles Raison

Last update posted

Nov 17, 2026

Last verified

Nov, 2026

Keywords

  • Aging
  • Longevity
  • Cognitive Function
  • Purpose
  • Meaning
  • Well-Being
  • Biomarkers

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-18. This information was provided to ClinicalTrials.gov by Charles Raison on 2026-11-17. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.